Cytokinetics, Inc.

Elan Pharmaceuticals, Inc.

Transition Therapeutics Ireland Limited

Jesse Cedarbaum

Fady Malik

Andrew A Wolff

John Mao

Provided is a method for treating ALS in a subject, comprising administering to the subject a therapeutically effective amount of riluzole and a therapeutically effective amount of CK-2017357. Also provided are methods of reducing the variability of riluzole exposure (e.g., Cand/or AUC) in a subject, methods of reducing the variability of riluzole exposure (e.g., Cand/or AUC) between two or more subjects, methods of decreasing the total daily dose of riluzole in a subject, methods of increasing the half-life of riluzole in a subject, methods for decreasing the frequency of riluzole dosing in the subject, and methods for reducing the incidence and/or severity of adverse events in a subject treated with riluzole.

Combination ALS therapy

The present disclosure relates to compositions and methods for reducing uric acid levels in a individual in need thereof. The present disclosure further relates to the treatment of hyperuricemia and diseases associated with high uric acid levels in mammals using scyllo-inositol.

Growing community of inventors

San Francisco, CA, United States of America

Jesse Cedarbaum